WO2003105923A3 - Utilisation de y-27632 comme agent destine a prevenir la restenose apres angioplastie d'arteres coronaires/implantation d'endoprothese - Google Patents

Utilisation de y-27632 comme agent destine a prevenir la restenose apres angioplastie d'arteres coronaires/implantation d'endoprothese Download PDF

Info

Publication number
WO2003105923A3
WO2003105923A3 PCT/US2003/018994 US0318994W WO03105923A3 WO 2003105923 A3 WO2003105923 A3 WO 2003105923A3 US 0318994 W US0318994 W US 0318994W WO 03105923 A3 WO03105923 A3 WO 03105923A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
coronary artery
stent implantation
prevent restenosis
artery angioplasty
Prior art date
Application number
PCT/US2003/018994
Other languages
English (en)
Other versions
WO2003105923A2 (fr
Inventor
Andrew R Marks
Steven O Marx
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Priority to AU2003245525A priority Critical patent/AU2003245525A1/en
Priority to EP03739153A priority patent/EP1551341A2/fr
Publication of WO2003105923A2 publication Critical patent/WO2003105923A2/fr
Publication of WO2003105923A3 publication Critical patent/WO2003105923A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention concerne une endoprothèse destinée à être implantée dans un vaisseau sanguin, ladite endoprothèse étant enrobée de Y-27632. L'invention concerne également un procédé permettant de traiter la resténose chez un patient, qui consiste à implanter à ce dernier une endoprothèse enrobée de Y-27632.
PCT/US2003/018994 2002-06-14 2003-06-12 Utilisation de y-27632 comme agent destine a prevenir la restenose apres angioplastie d'arteres coronaires/implantation d'endoprothese WO2003105923A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003245525A AU2003245525A1 (en) 2002-06-14 2003-06-12 Use of y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
EP03739153A EP1551341A2 (fr) 2002-06-14 2003-06-12 Utilisation de y-27632 comme agent destine a prevenir la restenose apres angioplastie d'arteres coronaires/implantation d'endoprothese

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38876002P 2002-06-14 2002-06-14
US60/388,760 2002-06-14

Publications (2)

Publication Number Publication Date
WO2003105923A2 WO2003105923A2 (fr) 2003-12-24
WO2003105923A3 true WO2003105923A3 (fr) 2004-03-25

Family

ID=29736538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018994 WO2003105923A2 (fr) 2002-06-14 2003-06-12 Utilisation de y-27632 comme agent destine a prevenir la restenose apres angioplastie d'arteres coronaires/implantation d'endoprothese

Country Status (3)

Country Link
EP (1) EP1551341A2 (fr)
AU (1) AU2003245525A1 (fr)
WO (1) WO2003105923A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067288A2 (fr) * 2006-11-27 2008-06-05 Yale University Procédés permettant d'inhiber la réaction à corps étranger face à des matériaux implantés
EP2177218A1 (fr) 2008-10-15 2010-04-21 Medizinische Universität Wien Thérapie régénératrice

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6344035B1 (en) * 1998-04-27 2002-02-05 Surmodics, Inc. Bioactive agent release coating

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344035B1 (en) * 1998-04-27 2002-02-05 Surmodics, Inc. Bioactive agent release coating
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating

Also Published As

Publication number Publication date
WO2003105923A2 (fr) 2003-12-24
AU2003245525A1 (en) 2003-12-31
EP1551341A2 (fr) 2005-07-13
AU2003245525A8 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
WO2004060318A3 (fr) Stents enrobes de medicaments et procedes d'utilisation leur convenant
WO2003047651A3 (fr) Appareil et procedes de mise en place de multiples extenseurs
AU2003234578A1 (en) Implantable prosthesis
WO2003009777A3 (fr) Administration d'agents a capacite therapeutique
DE60130032D1 (de) Vorrichtung zur Abgabe von therapeutischen Wirkstoffen
IL161335A (en) Coating of stents for preventing restenosis
WO2004075781A3 (fr) Endoprotheses vasculaires bioactives et leur mode d'emploi
WO2002074194A3 (fr) Revetement polymere multicouche medicamenteux
WO2005092244A3 (fr) Systeme de stent destine a empecher la restenose
AU2001253476A1 (en) Intravascular stent
IL153946A0 (en) Artificial vascular grafts, and methods of producing and using same
NO20063593L (no) Stentimplantat med bioaktive belegg
WO2006013261A3 (fr) Utilisation de fibroblastes gingivaux en therapie cellulaire vasculaire.
AU2742502A (en) Tissue-engineered vascular structures
MXPA05011620A (es) Dispositivos medicos y metodos para inhibir la proliferacion de celulas de musculo liso.
EP1023005A4 (fr) Procede de revetement de stents avec de l'adn et expression in vivo de genes de recombinaison a l'aide d'un stent recouvert d'adn
DE60312007D1 (de) Stents enthaltend eine molybdän/rhenium-legierung
WO2005055800A3 (fr) Revetement therapeutique endoluminal eluant un medicament
WO2003032809A3 (fr) Modulation de la reponse dependant de akt permettant de prevenir la restenose
WO2003059192A3 (fr) Endoprotheses enrobees d'exoenzyme c3 et utilisations de celles-ci pour le traitement et la prevention de la restenose
WO2003105923A3 (fr) Utilisation de y-27632 comme agent destine a prevenir la restenose apres angioplastie d'arteres coronaires/implantation d'endoprothese
WO2003061597A3 (fr) Utilisation d'inhibiteurs d'epoxyde hydrolase soluble afin d'inhiber la proliferation des cellules vasculaires des muscles lisses
WO2002087472A8 (fr) Administration de statines sur la base d'un stent pour prevenir la restenose
WO1998042327A3 (fr) Agent de remodelage vasculaire
WO2006105374A3 (fr) Optimisation de la pharmacodynamique d'agents therapeutiques pour le traitement de tissus vasculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003739153

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003739153

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003739153

Country of ref document: EP